Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI filing briefs

abrdn Life Sciences Investors (HQL)

HQL 8-K filings in 2023

Every material Form 8-K abrdn Life Sciences Investors filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 202313 on record in all
Latest filing in 2023Sep 12, 2023other
High impact (4-5)0of 1 brief
ToneNeutral1
Sep 12, 5:06 PM ET

Tekla Life Sciences Investors (HQL) replaces Deloitte with KPMG as auditor

Neutral other Written later 4.01

Deloitte & Touche resigned as the independent auditor of Tekla Life Sciences Investors on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management LLC and abrdn Inc. The fund's board approved KPMG LLP as its auditor on September 7, 2023, for the fiscal year ending September 30, 2023, and the filing reports no disagreements or reportable events with Deloitte.

  • Deloitte resigned on September 6, 2023, due to an anticipated independence issue linked to a pending Tekla Capital Management LLC and abrdn Inc. transaction.
  • The Audit Committee approved the resignation on September 7, 2023, and the board approved KPMG LLP the same day.
  • Deloitte's reports for the fiscal years ended September 30, 2022 and 2021 contained no adverse or disclaimer opinion and were not qualified or modified.
  • No disagreements or reportable events with Deloitte occurred in the two most recent fiscal years or the interim period through September 6, 2023.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn Life Sciences Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →